Alpine Immune Sciences, Inc. (ALPN) News

Alpine Immune Sciences, Inc. (ALPN): $9.90

-0.15 (-1.49%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALPN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 373

in industry

Filter ALPN News Items

ALPN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ALPN News Highlights

  • ALPN's 30 day story count now stands at 4.
  • Over the past 18 days, the trend for ALPN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about ALPN are TOUR.

Latest ALPN News From Around the Web

Below are the latest news stories about ALPINE IMMUNE SCIENCES INC that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses

SEATTLE, May 19, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company will present data from RUBY-1, a phase 1 study of povetacicept in healthy adult volunteers, at multiple upcoming scientific congresses, including participation in a poster tour at the European Congress of Rheumatology (EULAR) and an oral presentation at the European Hematology

Yahoo | May 19, 2023

Alpine Immune Sciences Reports First Quarter 2023 Financial Results

SEATTLE, May 11, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023.

Yahoo | May 11, 2023

Pinning Down Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) P/S Is Difficult Right Now

It's not a stretch to say that Alpine Immune Sciences, Inc.'s ( NASDAQ:ALPN ) price-to-sales (or "P/S") ratio of 10.9x...

Yahoo | May 5, 2023

Alpine Immune Sciences Announces Participation in the Bank of America Securities Healthcare Conference

SEATTLE, May 01, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the 2023 Bank of America Securities Healthcare Conference.

Yahoo | May 1, 2023

Even though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are still up 200% over 3 years

Alpine Immune Sciences, Inc. ( NASDAQ:ALPN ) shareholders might be concerned after seeing the share price drop 13% in...

Yahoo | March 27, 2023

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Q4 2022 Earnings Call Transcript March 23, 2023 Operator: Welcome to the Alpine Immune Sciences Fourth Quarter 2022 Earnings Call. Currently, all participants are in listen-only mode. As a reminder, this event is being recorded. I would now like to introduce Temre Johnson, Senior Director of Investor Relations and Corporate […]

Yahoo | March 27, 2023

Q4 2022 Alpine Immune Sciences Inc Earnings Call

Q4 2022 Alpine Immune Sciences Inc Earnings Call

Yahoo | March 24, 2023

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 23, 2023

Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

SEATTLE, March 23, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the fourth quarter ended December 31, 2022.

Yahoo | March 23, 2023

Alpine Immune Sciences to Present Povetacicept (ALPN-303) Phase 1 (RUBY-1) Study Data and Clinical Pharmacokinetic & Pharmacodynamic Modeling at Upcoming Scientific Conferences

SEATTLE, March 20, 2023--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and at the International Society of Nephrology World Congress of Nephrology (WCN).

Yahoo | March 20, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.628 seconds.